A phase ii multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

Marek Trnĕny, Gregor Verhoef, Martin J.S. Dyer, Dina Ben Yehuda, Caterina Patti, Miguel Canales, Andrés Lopez, Farrukh T. Awan, Paul G. Montgomery, Andrea Janikova, Anna M. Barbui, Kazimierz Sulek, Maria J. Terol, John Radford, Anna Guidetti, Massimo Di Nicola, Laure Siraudin, Laurence Hatteville, Sandrine Schwab, Corina OpreaAlessandro M. Gianni

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Sort by
Weight
Alphabetically

A phase ii multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

Fingerprint

Medicine & Life Sciences